These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

867 related articles for article (PubMed ID: 27563827)

  • 1. Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer.
    Choi C; Kwon J; Lim S; Helfman DM
    Oncotarget; 2016 Sep; 7(39):63466-63487. PubMed ID: 27563827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner.
    Nguyen DH; Catling AD; Webb DJ; Sankovic M; Walker LA; Somlyo AV; Weber MJ; Gonias SL
    J Cell Biol; 1999 Jul; 146(1):149-64. PubMed ID: 10402467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
    Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
    Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKT drives sustained motility following MEK inhibition via promoting SNAIL and AXL in MDA-MB-231 LM2.
    Kwon J; Helfman DM; Kim MY
    Biochem Biophys Res Commun; 2020 Jul; 528(1):92-98. PubMed ID: 32456793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2.
    Choi C; Helfman DM
    Oncogene; 2014 Jul; 33(28):3668-76. PubMed ID: 23995792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of the miR-141/200c cluster promotes the migratory and invasive ability of triple-negative breast cancer cells through the activation of the FAK and PI3K/AKT signaling pathways by secreting VEGF-A.
    Choi SK; Kim HS; Jin T; Hwang EH; Jung M; Moon WK
    BMC Cancer; 2016 Aug; 16():570. PubMed ID: 27484639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells.
    Aksamitiene E; Kholodenko BN; Kolch W; Hoek JB; Kiyatkin A
    Cell Signal; 2010 Sep; 22(9):1369-78. PubMed ID: 20471474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K pathway is involved in ERK signaling cascade activation by histamine H2R agonist in HEK293T cells.
    Alonso N; Diaz Nebreda A; Monczor F; Gutkind JS; Davio C; Fernandez N; Shayo C
    Biochim Biophys Acta; 2016 Sep; 1860(9):1998-2007. PubMed ID: 27316323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of the MEK5/ERK5 and PI3K/Akt signaling pathways synergistically reduces viability in triple-negative breast cancer.
    Wright TD; Raybuck C; Bhatt A; Monlish D; Chakrabarty S; Wendekier K; Gartland N; Gupta M; Burow ME; Flaherty PT; Cavanaugh JE
    J Cell Biochem; 2020 Feb; 121(2):1156-1168. PubMed ID: 31464004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells.
    Nam K; Son SH; Oh S; Jeon D; Kim H; Noh DY; Kim S; Shin I
    Oncotarget; 2017 May; 8(22):35804-35823. PubMed ID: 28415760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement for the PI3K/Akt pathway in MEK1-mediated growth and prevention of apoptosis: identification of an Achilles heel in leukemia.
    Blalock WL; Navolanic PM; Steelman LS; Shelton JG; Moye PW; Lee JT; Franklin RA; Mirza A; McMahon M; White MK; McCubrey JA
    Leukemia; 2003 Jun; 17(6):1058-67. PubMed ID: 12764369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways.
    Bouchard V; Demers MJ; Thibodeau S; Laquerre V; Fujita N; Tsuruo T; Beaulieu JF; Gauthier R; Vézina A; Villeneuve L; Vachon PH
    J Cell Physiol; 2007 Sep; 212(3):717-28. PubMed ID: 17443665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
    Yuen HF; Abramczyk O; Montgomery G; Chan KK; Huang YH; Sasazuki T; Shirasawa S; Gopesh S; Chan KW; Fennell D; Janne P; El-Tanani M; Murray JT
    Biosci Rep; 2012 Aug; 32(4):413-22. PubMed ID: 22668349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
    Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N
    Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.